The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
valbenazine · Kit
2 marketed package NDCs · 1 active manufacturer
Most dispensed: TOSYLATE 60 mg · Capsule · #30 capsules/bottle · TOSYLATE 40 mg · Capsule · #30 capsules/bottle · TOSYLATE 80 mg · Capsule · #30 capsules/bottle
Same drug class
Other molecules FDA puts in Vesicular Monoamine Transporter 2 Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Valbenazine in shortage right now?
- No. FDA does not currently list Valbenazine in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Valbenazine?
- 3 companies have marketed Valbenazine in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Valbenazine cost?
- The typical pharmacy pays about $283.32 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.